Cours de l'action
- Guerbet strengthens its leadership in innovative interventional radiology with the launch of two new microcatheters
- Gadolinium-based contrast agents: FDA Requirements December 2017 Guerbet LLC Update
- FDA Approves Guerbet’s Dotarem® (gadoterate meglumine) for Pediatric Patients Younger Than Two Years
Dotarem® (gadoterate meglumine) Injection is approved in the US for intravenous use and is the first and only macrocyclic and ionic gadolinium-based contrast agent in USA.
See Full Prescribing Information, including Boxed Warning